Inhibition/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
replication/NN
by/IN
a/DT
Tat-activated/JJ
,/,
transduced/VBN
interferon/NN
gene/NN
:/:
targeted/VBN
expression/NN
to/TO
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1-infected/JJ
cells/NNS
./.

We/PRP
have/VBP
examined/VBN
the/DT
feasibility/NN
of/IN
using/VBG
interferon/NN
(/(
IFN/NN
)/)
gene/NN
transfer/NN
as/IN
a/DT
novel/JJ
approach/NN
to/TO
anti-human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
therapy/NN
in/IN
this/DT
study/NN
./.
=====
To/TO
limit/VB
expression/NN
of/IN
a/DT
transduced/VBN
HIV-1/NN
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
-IFNA2/NN
(/(
the/DT
new/JJ
approved/JJ
nomenclature/NN
for/IN
IFN/NN
genes/NNS
is/VBZ
used/VBN
throughout/IN
this/DT
article/NN
)/)
hybrid/NN
gene/NN
to/TO
the/DT
HIV-1-infected/JJ
cells/NNS
,/,
HIV-1/NN
LTR/NN
was/VBD
modified/VBN
./.
=====
Deletion/NN
of/IN
the/DT
NF-kappa/NN
B/NN
elements/NNS
of/IN
the/DT
HIV-1/NN
LTR/NN
significantly/RB
inhibited/VBD
Tat-mediated/JJ
transactivation/NN
in/IN
T-cell/NN
lines/NNS
,/,
as/RB
well/RB
as/IN
in/IN
a/DT
monocyte/NN
line/NN
,/,
U937/NN
./.
=====
Replacement/NN
of/IN
the/DT
NF-kappa/NN
B/NN
elements/NNS
in/IN
the/DT
HIV-1/NN
LTR/NN
by/IN
a/DT
DNA/NN
fragment/NN
derived/VBN
from/IN
the/DT
5'-flanking/JJ
region/NN
of/IN
IFN-stimulated/JJ
gene/NN
15/CD
(/(
ISG15/NN
)/)
,/,
containing/VBG
the/DT
IFN-stimulated/JJ
response/NN
element/NN
,/,
partially/RB
restored/VBD
Tat-mediated/JJ
activation/NN
of/IN
LTR/NN
in/IN
T/NN
cells/NNS
as/RB
well/RB
as/IN
in/IN
monocytes/NNS
./.
=====
Insertion/NN
of/IN
this/DT
chimeric/JJ
promoter/NN
(/(
ISG15/NN
LTR/NN
)/)
upstream/JJ
of/IN
the/DT
human/JJ
IFNA2/NN
gene/NN
directed/VBD
high/JJ
levels/NNS
of/IN
IFN/NN
synthesis/NN
in/IN
Tat-expressing/JJ
cells/NNS
,/,
while/IN
this/DT
promoter/NN
was/VBD
not/RB
responsive/JJ
to/TO
tumor/NN
necrosis/NN
factor/NN
alpha-mediated/JJ
activation/NN
./.
=====
ISG15-LTR-IFN/JJ
hybrid/NN
gene/NN
inserted/VBN
into/IN
the/DT
retrovirus/NN
vector/NN
was/VBD
transduced/VBN
into/IN
Jurkat/NN
and/CC
U937/NN
cells/NNS
./.
=====
Selected/VBN
transfected/VBN
clones/NNS
produced/VBD
low/JJ
levels/NNS
of/IN
IFN/NN
A/NN
(/(
IFNA/NN
)/)
constitutively/RB
,/,
and/CC
their/PRP$
abilities/NNS
to/TO
express/VB
interleukin-2/NN
and/CC
interleukin-2/NN
receptor/NN
upon/IN
stimulation/NN
with/IN
phytohemagglutinin/NN
and/CC
phorbol/NN
myristate/NN
acetate/NN
were/VBD
retained/VBN
./.
=====
Enhancement/NN
of/IN
IFNA/NN
synthesis/NN
observed/VBN
upon/IN
HIV-1/NN
infection/NN
resulted/VBD
in/IN
significant/JJ
inhibition/NN
of/IN
HIV-1/NN
replication/NN
for/IN
a/DT
period/NN
of/IN
at/IN
least/JJS
30/CD
days/NNS
./.
=====
Virus/NN
isolated/VBN
from/IN
IFNA-producing/JJ
cells/NNS
was/VBD
able/JJ
to/TO
replicate/VB
in/IN
the/DT
U937/NN
cells/NNS
but/CC
did/VBD
not/RB
replicate/VB
efficiently/RB
in/IN
U937/NN
cells/NNS
transduced/VBN
with/IN
the/DT
IFNA/NN
gene/NN
./.
=====
These/DT
results/NNS
suggest/VBP
that/IN
targeting/VBG
IFN/NN
synthesis/NN
to/TO
HIV-1-infected/JJ
cells/NNS
is/VBZ
an/DT
attainable/JJ
goal/NN
and/CC
that/IN
autocrine/NN
IFN/NN
synthesis/NN
results/VBZ
in/IN
a/DT
long-lasting/JJ
and/CC
permanent/JJ
suppression/NN
of/IN
HIV-1/NN
replication/NN
./.